Company intelligence / Profile preview

Tibet Nuodikang Pharmaceutical

Lhasa, Tibet Autonomous Region, China

Ownership: Private
Development stage: Other

Overview

NuoDiKang Capsule is a commercialized Traditional Chinese Medicine used chiefly for cardiovascular indications, included on China's National Essential Drug List and has demonstrated substantial market growth (RMB57–62 million annual revenue in recent years)

Therapeutic areas: Cardiovascular
Modalities: Herbal medicineSmall molecule (derivatives of herbal compounds)
Industry: Biotech

Partnerships

AstraZeneca (commercial collaborations/license agreements via parent company)China Medical System Holdings (distribution/commercial platform)

Beyond the preview

Go deeper on Tibet Nuodikang Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tibet Nuodikang Pharmaceutical.

Explore the full profile